A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL)

Peer Review reports

Original Submission
23 Nov 2021	Submitted	Original manuscript
4 Apr 2022	Reviewed	Reviewer Report
1 Dec 2022	Author responded	Author comments - soichiro yoshida
Resubmission - Version 2
1 Dec 2022	Submitted	Manuscript version 2
Publishing
20 Feb 2023	Editorially accepted
6 Mar 2023	Article published	10.1186/s12894-023-01202-z

Back to article page